Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
1(8%)
Results Posted
17%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
1
8%
Ph phase_4
2
17%
Ph not_applicable
2
17%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(6)
Terminated(1)
Other(4)

Detailed Status

Completed6
unknown4
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (20.0%)
Phase 42 (40.0%)
N/A2 (40.0%)

Trials by Status

completed650%
recruiting18%
terminated18%
unknown433%

Recent Activity

1 active trials
Showing 5 of 12
completedphase_4

A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF

NCT04907825
terminatedphase_4

Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis

NCT03062319
completedphase_3

Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation

NCT01924065
recruiting

Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis

NCT04660747
unknown

Association of Obesity and Cardiovascular Outcomes in Atrial Fibrillation

NCT05645913
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04907825Phase 4

A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF

Completed
NCT03062319Phase 4

Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis

Terminated
NCT01924065Phase 3

Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation

Completed
NCT04660747

Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis

Recruiting
NCT05645913

Association of Obesity and Cardiovascular Outcomes in Atrial Fibrillation

Unknown
NCT04233515

Use of Oral Anticoagulants and Symptoms in Patients With Atrial Fibrillation in Örebro County

Completed
NCT03292666

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

Completed
NCT03904329

Obesity Paradox in Non Valvular Atrial Fibrillation Regarding Outcomes: Fact or Fiction

Unknown
NCT04935515Not Applicable

C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.

Completed
NCT04099238

Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care

Completed
NCT03573037Not Applicable

Anticoagulation After RFCA

Unknown
NCT03558295

CHAOS Registry Study

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12